Abstract
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
| Original language | English |
|---|---|
| Pages (from-to) | 412-423 |
| Number of pages | 12 |
| Journal | Protein and Peptide Letters |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2013 |
Fingerprint
Keywords
- Egf-p
- Farnesyltransferase inhibitors
- Interferon-alpha
- Interferon-beta
- Mtor
- Pegylated interferons
- Stats
- Type i interferons
ASJC Scopus subject areas
- Biochemistry
- Structural Biology
Cite this
Type i interferons : Ancient peptides with still under-discovered anti-cancer properties. / Caraglia, Michele; Dicitore, Alessandra; Marra, Monica; Castiglioni, Sara; Persani, Luca; Sperlongano, Pasquale; Tagliaferri, Pierosandro; Abbruzzese, Alberto; Vitale, Giovanni.
In: Protein and Peptide Letters, Vol. 20, No. 4, 04.2013, p. 412-423.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Type i interferons
T2 - Ancient peptides with still under-discovered anti-cancer properties
AU - Caraglia, Michele
AU - Dicitore, Alessandra
AU - Marra, Monica
AU - Castiglioni, Sara
AU - Persani, Luca
AU - Sperlongano, Pasquale
AU - Tagliaferri, Pierosandro
AU - Abbruzzese, Alberto
AU - Vitale, Giovanni
PY - 2013/4
Y1 - 2013/4
N2 - Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
AB - Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
KW - Egf-p
KW - Farnesyltransferase inhibitors
KW - Interferon-alpha
KW - Interferon-beta
KW - Mtor
KW - Pegylated interferons
KW - Stats
KW - Type i interferons
UR - http://www.scopus.com/inward/record.url?scp=84877959168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877959168&partnerID=8YFLogxK
U2 - 10.2174/092986613805290372
DO - 10.2174/092986613805290372
M3 - Article
VL - 20
SP - 412
EP - 423
JO - Protein and Peptide Letters
JF - Protein and Peptide Letters
SN - 0929-8665
IS - 4
ER -